Literature DB >> 2295067

Absence of IFNA and IFNB genes from human malignant glioma cell lines and lack of correlation with cellular sensitivity to interferons.

J Miyakoshi1, K D Dobler, J Allalunis-Turner, J D McKean, K Petruk, P B Allen, K N Aronyk, B Weir, D Huyser-Wierenga, D Fulton.   

Abstract

We report that 5 of 19 human malignant glioma cell lines have neither interferon alpha (IFNA) nor interferon beta (IFNB) genes that are detectable by Southern blotting. Of 5 other of these malignant glioma lines that have a single IFNB gene copy, 3 lack the IFNA genes entirely and two have one copy. One of the lines that lacks the IFNA genes entirely but has one copy of the IFNB gene has a rearrangement near the IFNB gene that is most easily interpreted as an insertion of a large segment of DNA (at least 50 kilobases) the 3' end of which is less than 1.3 kilobases 5' to the known regulatory sequences of the IFNB gene. In spite of the rearrangement, IFNB-specific RNA is highly inducible in this line by poly(I)-poly(C). The ability of interferon alpha or interferon beta to inhibit cell growth does not depend upon the presence or absence of the respective gene. This finding adds solid tumors to those tumor cell lines (acute lymphocytic leukemia, chronic myelogeneous leukemia) previously determined to lack the IFNA and IFNB genes (Diaz et al., Proc. Natl. Acad. Sci. USA, 85:5259-5263, 1988).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295067

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  29 in total

1.  Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers.

Authors:  T Nobori; K Takabayashi; P Tran; L Orvis; A Batova; A L Yu; D A Carson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

2.  Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines.

Authors:  H M Pomykala; S K Bohlander; P L Broeker; O I Olopade; M O Díaz
Journal:  Mol Cell Biol       Date:  1994-11       Impact factor: 4.272

Review 3.  Recent advances in immunobiology of brain tumors.

Authors:  M Tada; N de Tribolet
Journal:  J Neurooncol       Date:  1993-09       Impact factor: 4.130

4.  Characterization of three monoclonal antibodies that recognize the interferon alpha 2 receptor.

Authors:  O R Colamonici; F D'Alessandro; M O Diaz; S A Gregory; L M Neckers; R Nordan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

5.  DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.

Authors:  Kazuo Okemoto; Kazue Kasai; Benjamin Wagner; Amy Haseley; Hans Meisen; Chelsea Bolyard; Xiaokui Mo; Allison Wehr; Amy Lehman; Soledad Fernandez; Balveen Kaur; E Antonio Chiocca
Journal:  Clin Cancer Res       Date:  2013-09-20       Impact factor: 12.531

Review 6.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

7.  Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling.

Authors:  Dirk Holzinger; Carl Jorns; Silke Stertz; Stéphanie Boisson-Dupuis; Robert Thimme; Manfred Weidmann; Jean-Laurent Casanova; Otto Haller; Georg Kochs
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

Review 8.  Genetics of cancer predisposition and progression.

Authors:  K Schwechheimer; W K Cavenee
Journal:  Clin Investig       Date:  1993-06

Review 9.  Molecular cytogenetic quantitation of gains and losses of genetic material from human gliomas.

Authors:  B G Feuerstein; G Mohapatra
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

10.  Two phase II trials of temozolomide with interferon-alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme.

Authors:  M D Groves; V K Puduvalli; M R Gilbert; V A Levin; C A Conrad; V H Liu; K Hunter; C Meyers; K R Hess; W K Alfred Yung
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.